That warning letter, its seventh, said that in multiple meetings, Wockhardt officials "have repeatedly discussed and promised corporate-wide corrective actions." Yet, the FDA said, when its investigators return to or inspect another Wockhardt plant, they find the company persistently making the same mistakes. RELATED: FDA nails a third Wockhardt plant with a warning letter These observations came in a warning letter for Wockhardt's Morton Grove Pharmaceuticals site in Illinois, but the company has also received warning letters for plants in India, including one for an API plant in Ankleshwar, Gujarat, whose problems led to a complete response letter for a new-generation antibiotic that was under review for Chapel Hill, North Carolina-based Cempra.